A report on the 73th Annual Congress of the Japan Society of Obstetrics and Gynecology International Workshop for Junior Fellows: Risk‐reducing surgery for hereditary breast and ovarian cancer. Issue 11 (1st August 2021)

• Record Type: Journal Article
• Authors: Hirayama, Takashi; Inayama, Yoshihide; Odajima, Suguru; Yamanaka, Akina; Sekine, Masayuki; Terao, Yasuhisa; Koide, Keiko; Kuwabara, Yoshimitsu; Yahata, Hideaki; Yanaihara, Nozomu; Nagase, Satoru; Kobayashi, Yoichi; Sekizawa, Akihiko
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 47:Issue 11(2021)
• Page Start: 3761
• Page End: 3766
• Publication Date: 2021-08-01
• Subjects: BRCA -- hereditary breast and ovarian cancer -- risk‐reducing salpingo‐oophorectomy; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.14952
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: At the 73rd Annual Congress of the Japan Society of Obstetrics and Gynecology, young doctors from Japan and South Korea made presentations on the present condition of risk‐reducing surgery for hereditary breast and ovarian cancer (RRSO) in their respective country. RRSO was insured in Japan in April 2020, whereas in South Korea, it was insured 7 years earlier in 2013. In Japan, certification criteria have been set for facilities that perform RRSO, and the number of facilities is increasing, but regional disparities still exist in its distribution. The number of g BRCA 1/2 testing facilities is larger, and the cost is more affordable in South Korea than in Japan. Additionally, South Korea provides genetic counseling to a wider range of relatives compared to Japan. In the future, as the indications for the g BRCA 1/2 test have expanded as a companion diagnostic for the use of PARP inhibitors, it is expected that the number of candidates for the g BRCA 1/2 mutation test and RRSO will increase in Japan. It is important to increase the number of BRCA tests while maintaining the quality of genetic counseling in order to provide adequate information on BRCA mutations and RRSO for patients to support their decision. For the development of hereditary breast and ovarian cancer (HBOC) medical care, it is necessary to publish a nationwide database in Japan and continue to analyze and discuss the data based on the results.